logo
Share SHARE
FONT-SIZE Plus   Neg

Bristol-Myers Squibb, Pfizer Get Complete Response Letter For ELIQUIS

Bristol-Myers Squibb Co. (BMY) and Pfizer (PFE) said the U.S. Food and Drug Administration or FDA has issued a Complete Response Letter relating to the New Drug Application or NDA forELIQUIS for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. The Complete Response Letter requests additional information on data management and verification from the ARISTOTLE trial. Bristol-Myers Squibb and Pfizer would work closely with the FDA on the appropriate next steps for the ELIQUIS application. The FDA has not requested that the companies complete any new studies.

"There is a significant unmet need to reduce the risk of stroke in patients with atrial fibrillation," said Elliott Sigal, Executive Vice President and Chief Scientific Officer, Bristol-Myers Squibb. The companies continue to progress the ELIQUIS application for stroke prevention in atrial fibrillation in markets outside of the U.S., including the European Union and Japan, based on the ARISTOTLE and AVERROES studies.

The companies are committed to an ongoing clinical development program for ELIQUIS, which is estimated to comprise nearly 60,000 patients globally across multiple indications and patient populations and includes a total of nine completed or ongoing, randomized, double-blind Phase 3 trials.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
HSBC is reportedly laying off about 100 of its senior investment bankers worldwide, as the banking giant strives to curb operating costs. According to reports, the London-headquartered bank will eliminate managing director and director level employees at the Global Banking and Markets division, as... Samsung Electronics Co., Ltd. (SMSN.L, SSNNF.OB, SSNLF.OB) will reportedly blame faulty batteries for last year's Galaxy Note 7 fiasco. According to a Wall Street Journal report, Samsung's investigation of Galaxy Note 7 smartphones found that some batteries were irregularly sized while others had... Federal investigators have closed their probe of a fatal crash that involved a Tesla Motors Inc. car eight months ago. The regulators said they have found no safety defects in the vehicle's automated driving system and that Tesla's Autopilot-enabled vehicles did not need to be recalled.
comments powered by Disqus
Follow RTT